Skip to main content
AI Market Summary
Loading market intelligence...

Acceleron Pharma Inc (XLRN) Stock Forecast 2025 - AI Price Prediction & Analysis


Acceleron Pharma Inc (XLRN) AI Stock Price Forecast & Investment Analysis

Acceleron Pharma Inc Stock Price Chart and Technical Analysis

Loading Acceleron Pharma Inc interactive price chart and technical analysis...

Acceleron Pharma Inc (XLRN) - Comprehensive Stock Analysis & Investment Research

Deep dive into Acceleron Pharma Inc's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Acceleron Pharma Inc, including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Acceleron Pharma Inc: Acceleron Pharma Inc operates in the Manufacturing sector, positioning it as a large-cap market leader.

Acceleron Pharma Inc (Stock Symbol: XLRN) is a leading company in the Manufacturing sector , specifically operating within the Biological Product (except Diagnostic) Manufacturing industry.

The organization employs approximately 312 professionals worldwide and operates under the strategic leadership of CEO Habib Dable.

The company has established itself as a major market leader with significant institutional backing.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Acceleron Pharma Inc's revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Acceleron Pharma Inc: With $113M in annual revenue and -226.0% net margin, the company demonstrates developing profitability.

Annual Revenue: $113 million generating a -226.0% net profit margin .

Market Capitalization: $10904 million - Classified as a large-cap stock with institutional-grade stability.

Return on Equity (ROE): -31.6% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Acceleron Pharma Inc stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For Acceleron Pharma Inc: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Acceleron Pharma Inc stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Acceleron Pharma Inc's competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Acceleron Pharma Inc: Market positioning analysis based on available financial and operational metrics.

Acceleron Pharma Inc strategically competes in the highly dynamic Biological Product (except Diagnostic) Manufacturing marketplace, positioning itself as a dominant large-cap market leader with significant competitive moats and institutional investor confidence .

The company maintains a healthy 100.0% gross margin, indicating strong pricing power and operational efficiency.

Acceleron Pharma Inc (XLRN) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Acceleron Pharma Inc stock analysis.

Loading Acceleron Pharma Inc comprehensive fundamental analysis and insider trading data...

Deep dive into Acceleron Pharma Inc's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Acceleron Pharma Inc stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Acceleron Pharma Inc: With a P/E ratio of -42.36, the market sees the stock as potentially undervalued.

P/E Ratio -42.36x
P/B Ratio 15.23x
Market Cap $10904M
EPS $-4.22
Book Value/Share $11.74
Revenue/Share $1.85
FCF/Share $-2.05
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Acceleron Pharma Inc converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Acceleron Pharma Inc: An ROE of -31.6% indicates room for improvement in shareholder value creation.

ROE -31.6%
ROA -29.4%
ROIC -30.8%
Gross Margin 100.0%
Operating Margin -226.6%
Net Margin -226.0%
EBT Margin -226.0%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Acceleron Pharma Inc's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Acceleron Pharma Inc: A current ratio of 12.14 indicates strong liquidity.

Current Ratio 12.14x
Quick Ratio 10.92x
D/E Ratio 0.02x
Financial Leverage 1.09x
Interest Coverage -54.6x
Working Capital $833M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Acceleron Pharma Inc's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Acceleron Pharma Inc: Free cash flow of $-267M indicates cash challenges that need attention.

Operating Cash Flow $-261M
Free Cash Flow $-267M
Capital Spending $-5M
FCF/Sales -236.4%
CapEx/Sales 4.6%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Acceleron Pharma Inc uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Acceleron Pharma Inc: An asset turnover of 0.13x suggests room for improvement in asset utilization.

Asset Turnover 0.13x
Receivables Turnover 4.0x
Fixed Assets Turnover 4.1x
Days Sales Outstanding 92 days
Payables Period 466 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Acceleron Pharma Inc's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Acceleron Pharma Inc: With annual revenue of $113M, Acceleron Pharma Inc demonstrates solid business size.

Income Statement ($ Millions)
Total Revenue $113M
Operating Income $-255M
Net Income $-255M
R&D Expense $204M
SG&A Expense $122M
Cost of Goods Sold $2M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 88%
Cash & Short-term Investments 75%
Total Liabilities 9%
Short-term Debt 14%
Accounts Receivable 5%
Dividend & Shareholder Information
Shares Outstanding 61M

Latest Acceleron Pharma Inc Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Acceleron Pharma Inc (XLRN) stock price and investment outlook.

, source: Reuters

Merck's blood vessel disorder drug succeeds in late-stage study Merck & Co said on Monday a therapy it gained through the drugmaker's $11.5 billion acquisition of Acceleron Pharma last year met the ...

, source: NJBIZ

Merck announced on Nov. 22 that it completed its $11.5 billion acquisition of Acceleron Pharma Inc. “This is an important and strategic opportunity for our company to continue growing our ...

, source: AOL

Is Acceleron Pharma Inc (NASDAQ:XLRN) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have ...

, source: Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics ...

, source: AOL

Acceleron Pharma Inc. XLRN reported a loss of 34 cents in the second quarter of 2020, narrower than the Zacks Consensus Estimate of a loss of 55 cents but in line with the year-ago quarter’s reported ...

, source: Nasdaq

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the acquisition of Acceleron Pharma Inc. (Nasdaq: ...

Acceleron Pharma Inc Competitors & Peer Analysis - Manufacturing Sector

Comparative analysis of Acceleron Pharma Inc against industry peers and competitors in the Manufacturing sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio

Frequently Asked Questions - Acceleron Pharma Inc Stock Forecast

How accurate are Acceleron Pharma Inc stock predictions?

Our AI model shows a 8500% Spearman correlation coefficient for XLRN predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Acceleron Pharma Inc stock price forecasts?

Our analysis considers Acceleron Pharma Inc's financial metrics, Manufacturing sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Acceleron Pharma Inc a good investment in 2025?

Based on our AI analysis, Acceleron Pharma Inc shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Acceleron Pharma Inc forecasts updated?

Acceleron Pharma Inc stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Acceleron Pharma Inc Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Acceleron Pharma Inc stock.

My Portfolio

Investment Dashboard

Loading your portfolio...